The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I, first-in-human, open-label, dose-escalation study of U3-1565, a fully human anti-HB-EGF monoclonal antibody, in patients with advanced solid tumors.
Kathleen N. Moore
No relevant relationships to disclose
Johanna C. Bendell
No relevant relationships to disclose
Anthony J. Olszanski
No relevant relationships to disclose
Madhuri Desai
No relevant relationships to disclose
Mendel Jansen
No relevant relationships to disclose
Richard David Scheyer
No relevant relationships to disclose
Giorgio Senaldi
No relevant relationships to disclose
Patricia LoRusso
No relevant relationships to disclose